Oncology & Cancer

Pediatric cancer drug shows 93 percent response rate

A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.

Oncology & Cancer

Drop the C-word to reduce anxiety and overtreatment, say experts

Medical researchers are calling for the word 'cancer' to be dropped from some doctor-patient conversations in a bid to reduce patient anxiety and harm from over treatment.The appeal in today's BMJ follows mounting evidence ...

Oncology & Cancer

Q&A: Treatment for Hurthle cell thyroid cancer

Dear Mayo Clinic: Is it common to only have a partial thyroidectomy to remove Hurthle cells? My doctor is recommending this procedure, but I wonder if I should have my entire thyroid removed instead to eliminate the risk ...

Oncology & Cancer

Drug targeting BRAF mutation slows thyroid cancer, too

In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine ...

Oncology & Cancer

The Medical Minute: Thyroid cancer on the rise

September is Thyroid Cancer Awareness Month. With cases on the rise locally, nationally and globally, Dr. David Goldenberg, director of Head and Neck Surgery at Penn State Hershey Medical Center, hopes people will become ...

Surgery

Lymph node density predicts thyroid cancer outcomes

(HealthDay)—Lymph node density (LND) can help predict outcomes in patients with papillary thyroid cancer, according to a study published online Nov. 30 in JAMA Otolaryngology—Head & Neck Surgery .

page 1 from 4